# A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Source: https://onco.cc/trials/nct05859217/  
OnCo record `nct05859217` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cabozantinib and atezolizumab in lung cancer, run by Jun Zhang, MD, PhD, not yet recruiting.

## Summary

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) is a phase 2, interventional study registered as NCT05859217 by Jun Zhang, MD, PhD, with a registry enrolment figure of 40 participants, started 2024-12 and due to reach its primary completion in 2026-06. Interventions recorded: Cabozantinib; Atezolizumab. Conditions listed: Lung Cancer; NSCLC Stage IV; Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced NSCLC. Primary outcome: Objective response rate (ORR). Lung eligibility wording from the registry: "* Pathologically confirmed advanced/metastatic NSCLC, with PD-L1\<1% based on IHC using 22C3 antibody". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: Cabatezo-1
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05859217
- Phase: 2
- Setting: A Multi-center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatezo-1)
- Sponsor: Jun Zhang, MD, PhD
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT05859217: https://clinicaltrials.gov/study/NCT05859217

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Cabozantinib](https://onco.cc/drugs/cabozantinib/)
- companies: [Exelixis](https://onco.cc/companies/exelixis/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05859217.json